Tumor Treating Fields May Improve Glioblastoma Outcomes
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
CNS Cancers
Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
Patients With Meningioma Have Inferior Quality of Life Post-surgery
Researchers reviewed data from 1722 patients diagnosed with meningioma between 2006 and 2013 to determine whether the growth itself and/or treatment reduce patient QoL.
FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
Rindopepimut Not Associated With Prolonged Survival in Glioblastoma
At the preplanned interim analysis, the study was discontinued for futility.
Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
Glioblastoma: pp65 Vaccine With High-dose Temozolomide May Improve Survival
With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.
Next post in Brain Cancer
